Tim Boreham

1 week ago | stockhead.com.au | Tim Boreham

With some common types of cancers including breast and lung, therapies have developed at a rapid clip. The same can’t be said for pancreatic cancer, which is not among the most common tumours but ranks number one as the deadliest. Only 12% of patients will survive five years, compared to 21% for liver cancer and 23% for lung cancer. Pancreatic cancer is hard to treat because it is diagnosed late and the tumours are hard to access. About 80% of tumours are found at the advanced stage.

1 week ago | stockhead.com.au | Tim Boreham

Having produced more positive diagnostics results, Proteomics plans to launch its Promarker Endo device locally this year Immutep posts more positive trial results, this time for soft tissue sarcoma Broker values EBR Systems share price at more than double current worth after capital raising Proteomics International Laboratories (ASX:PIQ) has come up with more positive data to support its endometriosis diagnosis test Promarker Endo, presented – aptly – to the World Congress on Endometriosis,...

2 weeks ago | stockhead.com.au | Tim Boreham

Real estate investment trusts, or REITs are a key beneficiary of lower interest ratesThe sector is recovering from its post pandemic lows, but many REITs still trade below net asset backingCiti prefers retail REITs as landlords rediscover their pricing power and shoppers flock to the mallsWith the Reserve Bank of Australia this week dispensing 25 basis points of rates relief and signalling more to come, real estate investment trusts (REITs) look like being one of the ASX’s biggest beneficiaries.

2 weeks ago | stockhead.com.au | Tim Boreham

AFT Pharmaceuticals boosts revenue, but profits still lagTelix Pharmaceuticals chair and CEO reflect on a prosperous 2024 – and promise more riches to comeDimerix’s pivotal trail passes another safety checkThe bourse’s ‘forgotten’ drug maker, Kiwi-based AFT Pharmaceuticals (ASX:AFP) is confident of reaching its ‘aspirational’ target of $NZ300 million ($270 million) of revenue within the next two years.

2 weeks ago | stockhead.com.au | Tim Boreham

Cosette Pharmaceuticals’ $600 million tilt at Mayne Pharma is in perilAnalysts back Monash IVF after earnings update EBR Systems launches $55 million capital raising Investors have birched shares in takeover target Mayne Pharma (ASX:MYX) after the company today revealed a dispute with its suitor over what constitutes an ‘adverse material change’ to the business.